High expression of JAM-A has previously been associated with high tumor grade, larger tumor size, lower patient age, low PR levels, ER negativity, HER2 positivity, and Luminal B, HER2+ and basal subtypes of breast cancer [11,13]. This evidence concerns the gene F11R and breast cancer.